Treatment response following dupilumab treatment in one DDEB patient

Published: 4 August 2023| Version 1 | DOI: 10.17632/p4y7t4248w.1
Contributor:
Wilson Jr Aala

Description

Mendeley supplemental figure 3. Patient-reported VAS for itch was comparatively lower after 12 weeks of dupilumab treatment (VAS=4) relative to pre-treatment (VAS=8). The number and size of active lesions in the arms and legs were also visibly reduced.

Files

Steps to reproduce

Dupilumab was given subcutaneously at a loading dose of 600 mg followed by 300 mg biweekly for a total of 12 weeks in one of the six DDEB patients. Visual analog score (VAS) for itch was obtained at four-week intervals.

Institutions

National Cheng Kung University

Categories

Dermatology

Licence